PHOENIX

凤凰城

,

，

April 28, 2026

2026年4月28日

/PRNewswire/ --

/PRNewswire/ --

Trinity Capital Inc.

三一资本公司

(Nasdaq:

（纳斯达克：

TRIN

三因素指标

) (the 'Company'), a leading international alternative asset manager, today announced the commitment of $30 million in growth capital to

)（“公司”），一家领先的国际另类资产管理公司，今天宣布承诺提供 3000 万美元的增长资本用于

Iantrek

Iantrek

, a medical technology company and a leader in the bio-interventional ophthalmic surgery (BIOS) space.

，一家医疗技术公司，也是生物介入眼科手术（BIOS）领域的领导者。

Iantrek develops minimally invasive surgical technologies designed to treat chronic eye diseases, particularly glaucoma, aimed at restoring the eye's natural fluid outflow pathways and reducing ocular pressure. Its technology includes instrumentation and biologic tissue solutions that seek to help enable micro-interventional procedures for improved patient outcomes..

Iantrek 开发了用于治疗慢性眼病（尤其是青光眼）的微创手术技术，旨在恢复眼睛的自然液体流出通道并降低眼压。其技术包括仪器和生物组织解决方案，力求帮助实现微介入手术以改善患者的治疗效果。

'We believe Iantrek's innovative technology, strong clinical evidence, and early commercialization results position them well to be a leader in surgical ophthalmology,' said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital. 'We are pleased to support their team as they enter this next phase of rapid growth.'.

“我们相信Iantrek的创新技术、强大的临床证据和早期商业化成果使他们有望成为外科眼科领域的领导者，”Trinity Capital生命科学高级董事总经理Rob Lake表示。“我们很高兴支持他们的团队进入这一快速发展的新阶段。”

This debt facility follows a successful series C raise in 2025 which closed in 2025 and included lead equity investors USVP, Sectoral, aMoon, and Visionary Ventures. Trinity's growth capital will support Iantrek in accelerating commercial expansion of its product portfolio, advancing development and regulatory activities for pipeline products, scaling manufacturing and distribution capabilities, and strengthening market access initiatives to broaden physician and patient adoption..

这项债务融资是在2025年完成的C轮融资之后进行的，该轮融资的主要股权投资者包括USVP、Sectoral、aMoon和Visionary Ventures。Trinity的成长资本将支持Iantrek加速其产品组合的商业扩展，推动在研产品的开发和监管活动，扩大生产和分销能力，并加强市场准入计划以促进医生和患者的广泛采用。

'This financing is a strategic step to keep pace with growing physician demand for our platform. It positions us to accelerate adoption of AlloFlo Uveo, our lead commercial technology, and advance the next wave of bio-interventional innovation,' said Adam Szaronos, Chief Executive Officer of Iantrek..

“这笔融资是一个战略性步骤，旨在满足医生对我们平台日益增长的需求。它使我们能够加速推广我们的主要商业技术AlloFlo Uveo，并推动下一波生物干预创新的发展，”Iantrek首席执行官Adam Szaronos表示。

About Trinity Capital Inc.

关于三一资本公司

Trinity Capital Inc. (Nasdaq:

三一资本公司（纳斯达克：

TRIN

三角指标

) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Life Sciences.

）是一家国际另类资产管理公司，通过进入私人信贷市场为投资者寻求提供稳定回报。Trinity Capital 在五个不同的借贷领域中寻找并构建对资本充足、成长导向型公司的投资：赞助融资、设备融资、科技贷款、基于资产的贷款和生命科学。

As a long-term, trusted partner for innovative companies seeking tailored debt solutions, Trinity Capital has deployed more than $5.5 billion across over 463 investments since inception in 2008 (as of December 31, 2025). Headquartered in Phoenix, Arizona, Trinity Capital's dedicated team is strategically located across the United States and Europe.

作为寻求定制债务解决方案的创新公司的长期、可信赖的合作伙伴，自2008年成立以来（截至2025年12月31日），Trinity Capital已在超过463项投资中部署了超过55亿美元。Trinity Capital总部位于亚利桑那州凤凰城，其专业团队战略性地分布在美国和欧洲各地。

For more information on Trinity Capital, please visit .

有关三一资本的更多信息，请访问 。

trinitycapital.com

三一资本.com

and stay connected to the latest activity via

并通过以下方式保持与最新活动的联系

LinkedIn

领英

.

。

About Iantrek

关于Iantrek

Iantrek, Inc. (

Iantrek公司 (

www.iantrekmed.com

www.iantrekmed.com

) is a leader in bio-interventional ophthalmic surgery (BIOS), developing a portfolio of surgical technologies designed to restore natural ocular outflow pathways through biologic reinforcement rather than bypass or tissue removal. With the launch of AlloFlo Uveo in October 2025 and the U.S. introduction of AlloSpan Canal, Iantrek will be the only organization offering complementary surgical solutions targeting both natural outflow pathways—enabling a more comprehensive and physiologic approach to glaucoma intervention over the course of the disease.

）是生物介入性眼科手术（BIOS）的领导者，正在开发一系列旨在通过生物强化恢复眼部自然流出通道的外科技术，而非采用旁路或组织切除。随着AlloFlo Uveo于2025年10月推出，以及AlloSpan Canal在美国的引入，Iantrek将成为唯一一家提供针对两条自然流出通道的互补性手术解决方案的机构——从而在青光眼病程中实现更全面且符合生理学的干预方法。

For more information, visit .

有关更多信息，请访问 。

iantrekmed.com

iantrekmed.com

.

。

SOURCE Trinity Capital Inc.

来源：三一资本公司

21

21

%

%

more press release views with

更多新闻发布观点与

Request a Demo

请求演示